Flatiron Health

-23%

est. 2Y upside i

HealthcareSeries C

Rank

#3374

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Low

Extreme uncertainty due to stale 2016 valuation and missing revenue data.

Last updated: July 3, 2026

Bull (10%)+40%

Strategic sale at $2.66B (1.4x entry) driven by Roche divestiture or pharma buyer. Revenue assumed ~$300M grown 20% YoY, but highly speculative.

Base (45%)0%

Exit at stale $1.9B valuation with no growth inflection. No revenue data to support upside; multiple compression likely.

Bear (45%)-60%

Exit below $1B due to impaired competitive position and funding overhang. Preference stack consumes most proceeds, common stock loses ~60% vs entry.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

5640%

Total funding $314M on a $1.9B valuation (16.5% overhang); preferred holders get 1x liquidation preference.

Dilution Risk

high

Likely capital need within 2 years given divestiture and high cash burn; could increase shares by 20%.

Secondary Liquidity

none

No secondary market observed; no recent tender offers.

Other — 23 roles

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Flatiron Health's data — designed to show you've done your homework.

1
“How does Flatiron maintain exclusivity with oncology clinics vs IQVIA and Tempus?”
2
“What is the actual revenue run rate and path to profitability?”
3
“How does the Roche divestiture affect employee equity and liquidity timing?”

Our model estimates -23% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.